Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease

That is the title of my latest paper in JMCP with co-authors Jaehong Kim, Shanshan Wang, Moises Marin, Slaven Sikirica, and Mariam Anderson. The study abstract is below. BACKGROUND: Patients with type 1 diabetes (T1D) have a greater than 50% lifetime risk of developing comorbid chronic kidney disease (CKD). Glycemic control can reduce diabetes-related complications…

Read More